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Summary: The presence of a t(11;22)(q24;q12) translocation is one of the
characteristic features of the Ewing family of tumors. The detection of the
fusion gene product by RT-PCR using primers at both sides of the breakpoints
has been advocated as a diagnostic tool. By applying this technique appropriate
internal controls are required. We found that the use of normal non-rearranged
EWS mRNA as an internal control for RNA quality may lead to conflicting data.
We obtained PCR products of the expected size for the normal EWS mRNA in
both RNA and DNA samples, suggesting the existence of one or more EWS
pseudogenes. A 109 bp sequence at the 5' end of this PCR-product contained a
correctly spliced exon junction and was 97% homologous to the EWS cDNA
sequence. Similarly two such junctions were found in a 346 bp sequence of the
3' end, which was 89% homologous. Hence EWS should not be used as an
internal control for the RNA quality in a RT-PCR based test for the presence of
the tranSlOCation. O 1995 Academic Press, Inc.
The Ewing tumor family, consisting of typical and atypical Ewing's sarcoma and
peripheral primitive neuroectodermal tumor (PNET), shows little evidence of
differentiation at the light microscopic level. Therefore, distinction from other
small blue round cell tumors, like embryonal rhabdomyosarcoma, lymphoma or
neuroblastoma is difficult. 013 immunohistochemistry is an additional
diagnostic tools to identify selectively Ewing's sarcoma and PNET (1). However,
O1 3 immunoreactivity is not restricted to these tumors and has been detected
in some rhabdomyosarcomas and lymphomas as well (2-5). One highly specific
feature of the Ewing tumor family is the presence of the reciprocal chromosomal
translocation t(11;22)(q24;q12) in the tumor cells, present in 85-90% of the
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cases (6-9). The breakpoint has been cloned (10) and the two genes involved,
FLU on chromosome 11q24 and EWS on chromosome 22q12, were identified
(11,12). Several reports have described the RT-PCR detection of the resulting
EWS-FLI1 fusion transcript as a valuable diagnostic tool to identify Ewing's
sarcoma and PNET within the other small blue round cell tumors (13-17). Using
this technique even fusion transcripts resulting from subtle structural abnormali-
ties of 11q24 and 22q12 not found by cytogenetic analysis can be detected.
The EWS-FLI1 fusion transcript can be identified in up to 95% of Ewing's
sarcoma and PNET (18). In the remaining percentage of these tumors another
translocation, t(21;22)(q22;q12), is found, resulting in an EWS-ERG fusion
transcript which can also be detected by RT-PCR (18-20). Detection of the
fusion transcript is highly specific since several other tumors, including
rhabdomyosarcomas, small cell osteosarcomas and neuroblastomas are negative
(13,15-17). We applied the RT-PCR translocation detection method as described
(13-18) for implementation in routine diagnostic procedures. In this manuscript
we demonstrate that the use of the wild type EWS gene, recommended as a
control for RNA quality by Delattre et al (18), may lead to spurious signals when
the RNA sample is contaminated with DNA. Pre-treatment of RNA with RNAse
or DNAse before RT-PCR resulted in the identification of a novel EWS related
product which turned out to be most likely an intronless EWS pseudogene.
Since it is difficult to discriminate between PCR products of EWS-RNA and the
EWS-pseudogene, false negative diagnoses may result from these misleading
signals.
METHODS
Patient material: Snap frozen tissue, stored at -80°C, of 7 Ewing's sarcomas
and several other tumors was studied. The diagnosis Ewing's sarcoma was
based on histological, clinical-radiological and immunohistochemical data; all 7
cases studied showed immunoreactivity for the 013 antibody directed against
the MIC2 protein. In addition, we used a Ewing's sarcoma cell-culture with
cytogenetically proven t(11;22)(q24;q12) as a positive control. As a control for
specificity, irrelevant normal, or tumoral tissue was used of 1 5 patients (includ-
ing normal colon, ovarian carcinoma, melanoma of the eye, cervical carcinoma,
papillary thyroid carcinoma, colon carcinoma, carcinoma of the breast, squa-
mous cell carcinoma, rhabdomyosarcoma and small cell osteosarcoma).
DNA and RNA extraction: Total RNA extraction was performed with TRIzol
(Gibco BRL Life Technologies, Gaithersburg, MD, USA) according to the
manufacturer's recommendation. This commercial guanidinium/phenol based
reagent is claimed to be an improvement to the single-step RNA isolation
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method developed by Chomczynski and Sacchi (21). 15 sections of 20 /ym of
snap frozen tissue were cut using a microtome. The microtome blade was
thoroughly cleaned with 70% ethanol between cutting of individual specimens
to minimize cross contamination. A cell suspension of 6x106 cultured Ewing
sarcoma cells was centrifuged and the pellet was used for RNA isolation. DNA
isolation from irrelevant freshly collected blood samples was performed
according to the method of Miller et al (22). The DNA and RNA concentration
and purity was determined by measuring the absorption at 260 and 280 nm at a
spectrophotometer (Ultrospec plus, LKB Biochrom, Bromma, Sweden).
Reverse transcription: One or two fjg of total RNA was reverse transcribed using
100 ng oligo dT (Boehringer Mannheim, Germany) in a total volume of 20 //I
containing 1U RNAsin, 1 mM dNTP, 100 mM Tris-HCI, pH 8.3, 80 mM KCI, 12
mM MgCI2, 2 mM DTT and 5U AMV-reverse transcriptase (Boehringer
Mannheim, Germany). The tubes were incubated at 37°C for 1 hour. cDNAs
were stored at -20°C.
Polymerase Chain Reaction: One //I of the resulted cDNA was used directly for
amplification. PCR was performed in a total volume of 50 jj\, containing 30
pmol of each primer, 0.2 mM dNTP (all purchased from Pharmacia, Woerden,
the Netherlands), 50 mM KCI, 10 mM Tris (pH 8.3), 0.2 mg/ml Bovine Serum
Albumin (BSA), 2 mM MgCI2 and 1U Ampli-Taq (Perkin Elmer, Norwalk, CT,
USA). All standard precautions were taken to prevent contamination during
PCR-reaction. Thermal cycling was performed in a programmable heat block
(Perkin Elmer Cetus, Norwalk, CT, USA). The amplification conditions for all
primer sets used were as described (18); 30 cycles with each cycle consisting
of denaturation at 94°C for 30 sec, annealing at 68°C for 1 min and elongation
at 72°C for 1 min. Ten //I of each PCR-product was subjected to electrophoresis
in 1.2% agarose gels. A 100 bp length marker (Gibco BRL, Life Technologies,
Gaithersburg, MD, USA) was used to estimate the sizes of the obtained PCR-
products. Amplification products were visualized by staining with ethidium
bromide. To test for the presence of the EWS-FLI1 hybrid transcript, amplifi-
cation was carried out with primers 22.8 and 11.11. These primers were
prepared according to published sequences (18,20). EWS-FLI1 fusion PCR
products vary in sizes ranging from 205 to 820 basepairs (12-14).
Controls: For confirmation that each RNA sample tested could potentially yield
products after RT-PCR, transcripts of the wild type EWS or the housekeeping
gene HPRT were amplified simultaneously under the same conditions as
demanded for detection of fusion transcripts. For amplification of part of the
wild type EWS cDNA, the same EWS forward primer (22.8) was used in
combination with a reverse primer (22.4) (18). HPRT cDNA was amplified with
primers hum1 (5'-ACCGGCTTCCTCCTCCTGAGCAGTC-3') and hum2 (5'AG-
GACTCCAGATGTTTCCAAACTCAACTT-3'). To exclude PCR products resulting
from DNA rather than RNA, two approaches were used. First, to test for the
presence of contaminating genomic DNA in the RNA samples, each RNA sample
was also incubated with a similar mixture without addition of AMV reverse
transcriptase. Second, RNAse and DNAse treatments were performed; 2 fjg of
total RNA or DNA were treated with 1U RQ1 RNAse-free-DNAse (Promega,
Madison, Wl, USA) or RNAse (Stratagene, La Jolla, CA, USA) in a total volume
of 12 fj\ containing 50 mM KCI, 10 mM Tris (pH 8.3), 0.2 mg/ml BSA, 2.5 mM
MgCI2 and 40 U RNAsin (Promega, Madison, Wl, USA). Samples were
incubated at 37°C for 1 hour and DNAse was inactivated by incubation at
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80°C for 10 min. As a positive control for the EWS-FLI1 fusion transcript, RNA
of cultured Ewing cells, with cytogenetically confirmed t(11;22) was included in
each test. As a negative control H20 was used as a template in each test to
exclude contamination of primers, water or reagents.
Sequence analysis: The approximately 1200 bp PCR product that resulted from
amplification of genomic DNA using M13-tailed primers 22.4 and 22.8 (CGAC-
GTTGTAAAACGACGGCCAGT-22.8 and CAGGAAACAGCTATGAC-22.4) was
sequenced. A second PCR was done with biotin labeled M13 primers using the
product of the first PCR as template. The resulting PCR products were purified
using the EasyPrep kit (Pharmacia Biotech, Uppsala, Sweden) according to the
manufacturer's recommendations. PCR products were alkali-denatured and
single-strand fragments were captured using Dynabeads (ITK diagnostics,
Uithoorn, the Netherlands). Sequencing reactions were performed on the
Automated Laser Fluorescence DNA sequencer (Pharmacia Biotech, Uppsala,
Sweden) according to the manufacturer's recommendations for the Autoread kit
(Pharmacia biotech, Uppsala, Sweden). Computer assisted analysis of the
obtained results was performed. Another approach was made using primers
22.4 and 22.8 (without M13 tails) which were radioactively labeled with [32P]-
dATP using T4 polynucleotide kinase. Sequencing was performed using the USB
cycle sequencing kit (U.S.B., Cleveland, Ohio, USA) and thermal cycling took
place in a programmable heatblock (Perkin Elmer, Norwalk, CT, USA) with 30
cycles consisting of annealing at 65°C and denaturation at 95°C. Samples
were subjected to electrophoresis on standard denaturing 6% polyacrylamide
gels containing 7M urea. Autoradiography was performed by exposition to X-ray
films (Kodak) for 24-72 hours. Nucleotide sequences were determined by visual
inspection. Obtained sequences were not verified by sequencing the opposite
strand.
RESULTS
Reverse transcription and PCR reaction: In all seven Ewing's sarcomas tested
and the Ewing's cells in culture with a proven t(11;22), EWS-FLI1 fusion
transcripts were detected (Fig.1). No products were seen in the negative con-
trols (H20) as well as in 15 carcinomas and sarcomas not belonging to the
Ewing tumor family. The EWS internal control yielded a PCR product of the size
as expected from previous studies (18) in all RNA samples tested. However,
omission of reverse transcriptase, amplification of genomic DNA and
pretreatment of DNA with RNAse revealed a product of the same size (Fig. 2A).
After DNAse pretreatment of RNA samples, no PCR product was obtained
anymore. These results indicate that the obtained products resulted from
amplification of DNA, instead of reverse transcribed RNA. When we used the
hypoxanthine phosphoribosyltransferase (HPRT) control as suggested by Foss et
al (23), PCR products of the expected size (747 bp) were obtained only when
RNA, after reverse transcription, was used as template (Fig. 2B). After
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Figure 1. RT-PCR analysis of Ewing's sarcomas. Total RNA was extracted from
archival fresh frozen tumor tissue, followed by RT-PCR analysis using primers
on exon 7 of EWS and exon 9 on FLU. Products were electrophoresed on a
1.2% agarose gel and visualized by staining with ethidium bromide. 1-7:
Ewing's sarcomas, + : Ewing's sarcoma with cytogenetically proven
t(11;22)(q24;q12), bl: H2O as a negative control, L: 100 bp size marker.
pretreatment of DNA with RNAse and with omission of reverse transcriptase, no
PCR product could be obtained.
Sequence analysis: From both the 5' and the 3' end of the EWS PCR product a
partial nucleotide sequence could be obtained (Fig. 3). A sequence of 109
basepairs was obtained using the forward primer which showed 97% homology
to the published sequence of the EWS-cDNA (12). In this region a correctly
spliced junction between exons 7 and 8 in EWS (24) is present. From the 3'
end, a nucleotide sequence of 346 basepairs could be obtained. Thirty-two
mutations were found in this part relative to the EWS cDNA sequence (89%
homology). Two splice junctions at the predicted positions in EWS, one
between exons 14 and 15 and one between exons 15 and 16, are present. If
the obtained sequences are translated in the same reading frame as the original
EWS gene, various premature stops are observed.
DISCUSSION
The presence of either the EWS-FLI1 or the EWS-ERG fusion transcript is
predicted to become the diagnostic criterium for the Ewing's tumor family in the
future. The application of the RT-PCR translocation detection test for diagnostic
purposes therefore requires appropriate controls for the validity of the test. To
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1+ 2 + 3-f 4+ 5+ 6+ 1- 2- 3- 4- 5- 6- bl L
B
1+ 2+ 3+ 4+ 5+ 6+ l- 2- 3- 4- 5- 6- bl L
Figure 2. Testing and comparison of two RT-PCR internal controls for RNA
quality and succeeding of the reverse transcription. Products were electrop-
horesed through 1.2% agarose gels and visualized using ethidium bromide
staining. +: reverse transcriptase added in RT step, -: H20 added instead of
reverse transcriptase in RT step, 1 : RNA treated with DNAse and RNAse, 2:
RNA treated with DNAse, 3: DNA treated with DNAse, 4: DNA treated with
RNAse, 5: RNA not treated, 6: DNA not treated, bl: H20 as a negative control,
L: 100 bp size marker. Both RNA and DNA were extracted from Ewing's
sarcoma cells in culture using TRIzol.
A: Amplification of EWS internal control, as suggested by Delattre et al.(18). B:
amplification of the HPRT housekeeping gene.
exclude contamination, a sample with H2O should be included in each test. To
exclude false negative diagnoses, an appropriate and reliable internal control to
ensure RNA quality and reverse transcription is required since a positive internal
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l l l * * l * * l l
GACTATGTAT
GGAAAAATGG




1 1 1 1 1 1 1 * 1 1 I l l l l l l * * !
GTAAGGCTCC AAAGCCTAGA
GTGGTGATC GTGGCAGAGG
M l 1 * 1 1 1 M l l l l l l l l
GTG.TAATC GTGGCAGAGG
GATCGTGGTGTGGCCTCATG
I M I I M M
. AGCCTCATG GATCATGGTG
GTGGAGACAG
1 1 * 1 1 1 1 1 1 1
GTAGAGACAG
TTTGGTGGAG
M l l l l l l l l
TTTGGTGGAG
GGAACAGATG
i*H " I I I
GTAACCAATG
AGGTGGCTTC
h l l l M I M
AAGTGGCTTC
GAAGACGAGG
1 1 1 1 1 1 * 1 1 1
GAAGACAAGG
GGAGGAAGAA
M l l l l l l l l
GGAGGAAGAA
GGCTTCCTC C
I M I M M M
GGCTTCCTCCC
TGGCCCTGGT
I M I M M M
TGGCCCTGGT
GTCCCGGTGG
M l l l l l l l l
GTCCCGGTGG
CGTGGTGGCC
I M I I M I l
CGTGGTGG.C
TGGCCCTGGG
M l l l l l l l l
TGGCCCTGGG
GAGGAGGACG
I M M M M I
GAGGAGGACG
ATAA | AGGCGA GCACCGTCAG GAGCGCAGAG
22.4 (reverse-
Nucleotide sequences of parts of the EWS pseudogene (in italics)
obtained by DNA sequencing are compared with the EWS cDNA sequence
which was retrieved from the genome database (accession nr X66899). Exon
junctions (24) are indicated with bars and primer sequences are underlined. (?:
nucleotides that could not be determined .: deletion *: mutation I: insertion).
A high percentage of homology (89% and 97%), three correctly spliced exon
junctions and numerous stop codons were found.
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control with a negative result for the fusion product determines that the
diagnosis should be reconsidered.
In this manuscript we report the existence of an EWS pseudogene. Pseudo-
genes are homologs of active genes but they do not contain any of the introns
and a polyA tail at the 3'-end can be found (25). Pseudogenes originate from re-
trotransposition (25) and the EWS mRNA may have been converted into DNA,
which in turn was inserted into the genome. Pseudogenes do not encode
functional proteins and the percentage of homology to the cDNA of the original
gene decreases during evolution. A wide range of genes, especially the
housekeeping genes, have been shown to have one or several retrotransposed
homologs in the mammalian genome like, for instance, human ferrochelatase
(26), dihydrolipoyl succinyltransferase (E2k) (27) and glyceraldehyde-3-phospha-
te dehydrogenase (23). To our knowledge no such genes have been reported to
exist for EWS so far. We show that the length of the EWS PCR-products
obtained by amplification of genomic DNA is identical to the size expected on
basis of the cDNA sequence. By sequencing the PCR product obtained by
amplification of DNA extracted from an irrelevant blood sample, we could
determine a nucleotide sequence at both ends of the PCR product. These parts
revealed a high percentage (97% and 89% respectively) of homology to the
sequence of the EWS cDNA. Furthermore, three splice junctions were present at
predicted positions and multiple stop codons were found. These results strongly
indicate the presence of at least one EWS pseudogene in the human genome.
Future studies should reveal whether this pseudogene is transcribed and where
it is located in the genome.
Pseudogenes complicate the PCR analysis of (parts of) the original gene
(23,26,28). Consequently, primersets which detect such pseudogenes are not
recommended as internal control for RT-PCR based tests. An appropriate control
for the RT-PCR translocation detection would be a gene, consistently expressed
across a wide range of physiologic conditions in all cells and tumor cells.
Therefore we tested PCR amplification of the housekeeping gene hypoxanthine
phosphoribosyltransferase (HPRT) mRNA as suggested by Foss et al (23).
Amplification of HPRT could be performed under exactly the same conditions as
amplification of the EWS-FLI1 fusion transcript. PCR products of the expected
size were only observed when RNA, after reverse transcription, was used as
template. Therefore we recommend the HPRT primer set used in this study as
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an appropriate and reliable control for application in the RT-PCR translocation
detection for the Ewing tumor family.
With the molecular genetic elucidation of specific translocations like t(X;18)-
(p11.2;q11.2) in synovial sarcoma (29), t(12;22)(q24;q12) in Clear Cell
Sarcoma (30) and t(3;12)(q35;q14) in alveolar rhabdomyosarcoma (31), it might
be expected that RT-PCR procedures will be increasingly implemented in routine
diagnostic procedures. Therefore, in general we would suggest three different
controls for translocation detection protocols; 1.) as a positive control RNA of a
tumor (preferably of a tumor cell line for continuous supply) with a
cytogenetically and/or molecular proven hybrid transcript; 2.) as a negative
control H20 as template to exclude contamination; 3.) an internal control to
ensure RNA quality and reverse transcription for each test sample; preferably a
housekeeping gene that can be amplified under exactly the same PCR conditions
as the fusion product. In any way primer sets to be used for internal control
should be thoroughly tested to ascertain that no pseudogenes can be detected,
thus to exclude false positive internal control results which may lead to false
negative diagnoses. This is the only way RT-PCR translocation detection tests
can be reliably implemented in routine diagnostic procedures.
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